Pancreatic Cancer Research

ResearcherActive in the last 2 years

Shusei Tominaga

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5110143977. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
0
Collaborators
2
Papers, trials and grants by year

2020: 3 papers · 2021: none · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 10

  1. Poor Performance Status, Diabetes Mellitus, and Statin Use Are Risk Factors for Decreased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Therapy i… Last author DOI 10.1097/mpa.0000000000002565↗
  2. Prognostic Significance of Number of Liver Metastases in Patients With Advanced Pancreatic Cancer Receiving Nab-paclitaxel Plus Gemcitabine. Last author DOI 10.21873/cdp.10592↗
  3. Prognostic Significance of ABO Blood Type in Patients with Advanced Pancreatic Cancer Treated with Nab-Paclitaxel Plus Gemcitabine. Last author DOI 10.1097/mpa.0000000000002515↗
  4. Clinical Significance of Increased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Treatment in Patients With Advanced Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002269↗
  5. Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer. Last author DOI 10.1097/md.0000000000029532↗
  6. Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan. Last author DOI 10.1097/mpa.0000000000001942↗
  7. Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002013↗
  8. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Last author DOI 10.1002/cnr2.1215↗
  9. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with a… Last author DOI 10.1002/cnr2.1289↗
  10. Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001596↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kiyotsugu Iede · 10 shared papers, 2020–2026 · strength 1.87
  2. Tsukasa Tanida · 6 shared papers, 2022–2026 · strength 1.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.